Pluronic block copolymers for overcoming drug resistance in cancer.
about
Nanoplatforms for constructing new approaches to cancer treatment, imaging, and drug delivery: what should be the policy?Recent insights in nanotechnology-based drugs and formulations designed for effective anti-cancer therapyExploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunitiesPolymers influencing transportability profile of drugCan nanomedicines kill cancer stem cells?Drug Carriers: Not an Innocent Delivery ManPluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiersAdding vitamin E-TPGS to the formulation of Genexol-PM: specially mixed micelles improve drug-loading ability and cytotoxicity against multidrug-resistant tumors significantlyCurrent approaches to enhance CNS delivery of drugs across the brain barriersPolymeric micelles, a promising drug delivery system to enhance bioavailability of poorly water-soluble drugs.Doxorubicin as a molecular nanotheranostic agent: effect of doxorubicin encapsulation in micelles or nanoemulsions on the ultrasound-mediated intracellular delivery and nuclear trafficking.Potential applications and human biosafety of nanomaterials used in nanomedicineCellular distribution studies of the nitric oxide-generating antineoplastic prodrug O(2) -(2,4-dinitrophenyl)1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate formulated in Pluronic P123 micelles.Synthesis, characterization, and biological verification of anti-HER2 indocyanine green-doxorubicin-loaded polyethyleneimine-coated perfluorocarbon double nanoemulsions for targeted photochemotherapy of breast cancer cellsCerium oxide nanoparticles in cancerPolymeric nanomedicine for cancer MR imaging and drug deliveryDegradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release.A Novel Docetaxel-Loaded Poly (ε-Caprolactone)/Pluronic F68 Nanoparticle Overcoming Multidrug Resistance for Breast Cancer Treatment.Pluronics and MDR reversal: an update.Carboxymethylcellulose-based and docetaxel-loaded nanoparticles circumvent P-glycoprotein-mediated multidrug resistance.Enhanced brain delivery of lamotrigine with Pluronic(®) P123-based nanocarrierDevelopment of a novel orthotopic non-small cell lung cancer model and therapeutic benefit of 2'-(2-bromohexadecanoyl)-docetaxel conjugate nanoparticles.Drug resistance in breast cancer cells: biophysical characterization of and doxorubicin interactions with membrane lipids.The effect of co-delivery of paclitaxel and curcumin by transferrin-targeted PEG-PE-based mixed micelles on resistant ovarian cancer in 3-D spheroids and in vivo tumors.Tuning core vs. shell dimensions to adjust the performance of nanoscopic containers for the loading and release of doxorubicinInteraction, solubilization and location of p-hydroxybenzoic acid and its sodium salt in micelles of moderately hydrophilic PEO-PPO-PEO triblock copolymers.An essential relationship between ATP depletion and chemosensitizing activity of Pluronic block copolymers.Structural parameters governing activity of Pluronic triblock copolymers in hyperthermia cancer therapyDual-functional c(RGDyK)-decorated Pluronic micelles designed for antiangiogenesis and the treatment of drug-resistant tumor.Enhanced stability of polymeric micelles based on postfunctionalized poly(ethylene glycol)-b-poly(γ-propargyl L-glutamate): the substituent effectNanoscale polymer carriers to deliver chemotherapeutic agents to tumours.The use of silica coated MnO nanoparticles to control MRI relaxivity in response to specific physiological changes.Pluronic P105/F127 mixed micelles for the delivery of docetaxel against Taxol-resistant non-small cell lung cancer: optimization and in vitro, in vivo evaluation.The combined use of paclitaxel-loaded nanoparticles with a low-molecular-weight copolymer inhibitor of P-glycoprotein to overcome drug resistanceBlock copolymer micelles as delivery vehicles of hydrophobic drugs: micelle-cell interactions.Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancerDocetaxel-loaded multilayer nanoparticles with nanodroplets for cancer therapy.Poly(2-oxazoline)s as polymer therapeutics.Pluronic mixed micelles overcoming methotrexate multidrug resistance: in vitro and in vivo evaluation.A simple way to enhance Doxil® therapy: drug release from liposomes at the tumor site by amphiphilic block copolymer.
P2860
Q24599399-FA98D12D-6B15-4BC1-B7AA-5A9885A2C828Q26745710-BC0DE8B2-A990-4B56-8952-2B7B6DB7EED3Q26828930-79D93DFD-4FF6-478C-8543-753A9B9B5C28Q26862824-63819FF0-25FB-423E-96F8-A955D808658FQ27022017-F3EB5858-4E84-4405-984F-187D5AC193FAQ28082414-07B77974-4275-4F55-8A7B-2C9DEE26E43CQ28282826-20E90021-473A-4CB9-918D-BE67BE66824CQ28545246-38A80FDB-D57C-4F1F-A9A4-763F9606D675Q30437835-29C6A45F-ECE6-4D4D-8D22-C2E1ADF6A7C2Q30451024-EA3A8905-5C0A-402B-8725-58BFA476F804Q30472420-1E091C89-BF5A-4469-801B-5C450A5EB8BBQ32944368-1566B80A-B175-4E98-907E-FAD5574F3371Q33565776-76F802E3-7FB6-4D30-A635-48BED610A7F4Q33706296-7C61DF30-8C70-4DD0-97B8-FD0FEDC561FEQ33706871-336787A4-6991-4F48-887C-A667819AB8F0Q33773418-4D1AFDDA-2CA6-4191-949C-FEDA8D74DB85Q33902253-1DE935B6-B8F9-4B64-8582-069769CC7571Q33949801-3F6603EA-56F8-480F-8E21-3F9097850A36Q34005678-FA778FE6-E3E1-45CA-A7DA-A550A6896169Q34005719-FDA3A5C5-1123-4551-B18A-A0DD7560FF19Q34075276-1D8A64E9-E82D-44F5-9140-5AEBC8D3BE56Q34289406-07A37C5D-5F30-432B-8394-FFCDCDC3EC3FQ34384873-6903F1D4-B8F6-4136-A72C-9ACC8F01FF43Q34615075-7621E518-D86B-422C-8B58-E33F65D0413DQ35058263-4E3BD876-8F40-4BD6-BA5E-27268454DDF4Q35172745-EE0F2A9A-595D-4A11-91E0-4775C093E3E4Q35204550-EC272B0A-FC65-42E2-951E-A66AAF8E0A00Q35800826-875F86EE-B79F-4E99-A09A-A3EABB718560Q35918831-7370B7E6-BEFC-4A19-AEA7-8A7262DBEC60Q36070273-54480E28-6373-4263-9419-C2A97463670FQ36327049-0A47A35C-D2AA-4573-9ED7-C2DE00CFD18FQ36486445-ABA9D784-ED12-4A5E-84CE-355B448EA638Q36520778-A9624830-22E5-4C6F-9490-F7EFFC06BCB7Q36567533-C7C0CB08-9429-4AD0-8264-2BA2D2A13222Q36648447-1A9B7857-718F-42AA-9E26-EAFE5C7548B4Q36694177-D75EC1EA-0CD3-44AD-9F31-8AD3DD8DD727Q36710248-FD13AF0B-2978-448D-B4DC-BD9CDDD351B9Q36716915-9EE13FFF-618C-4229-80B2-78B601B62C42Q36779964-2159C628-8979-4A7F-8EEC-03DEAC735A29Q36867763-75B459BD-1506-4C35-92FF-07A5B6BD906E
P2860
Pluronic block copolymers for overcoming drug resistance in cancer.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Pluronic block copolymers for overcoming drug resistance in cancer.
@ast
Pluronic block copolymers for overcoming drug resistance in cancer.
@en
Pluronic block copolymers for overcoming drug resistance in cancer.
@nl
type
label
Pluronic block copolymers for overcoming drug resistance in cancer.
@ast
Pluronic block copolymers for overcoming drug resistance in cancer.
@en
Pluronic block copolymers for overcoming drug resistance in cancer.
@nl
prefLabel
Pluronic block copolymers for overcoming drug resistance in cancer.
@ast
Pluronic block copolymers for overcoming drug resistance in cancer.
@en
Pluronic block copolymers for overcoming drug resistance in cancer.
@nl
P1476
Pluronic block copolymers for overcoming drug resistance in cancer
@en
P2093
Elena V Batrakova
Valery Yu Alakhov
P304
P356
10.1016/S0169-409X(02)00047-9
P407
P50
P577
2002-09-01T00:00:00Z